MDMA use in medical trials U.S. 2017

This statistic shows the percentage of U.S. adults who supported allowing researchers to conduct medical trials with MDMA as of 2017. According to the survey, 61 percent of respondents supported the use of MDMA in medical trials.

Percentage of U.S. adults who supported allowing researchers to conduct medical trials with MDMA as of 2017

Characteristic	Percentage of respondents
Support	61%
Oppose	14%
Don't know	25%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

2017

More information

Region

North America, United States

Survey time period

June 2 to 5, 2017

Number of respondents

1,125 respondents

Age group

18 years and older

Special properties

U.S. adults

Supplementary notes

Original question: In 2016, The FDA approved MDMA (also known as ecstasy) for Phase 3 clinical trials as a treatment for post-traumatic stress disorder (PTSD) — a final step before possible approval as a prescription drug. One study showed that with 3 doses of MDMA administered under a psychiatrist's guidance, the patients reported a 56% decrease of severity of symptoms on average. At the end of the study, 66% no longer met the criteria for having PTSD — improvements lasted more than a year after therapy. Do you support or oppose similar medical trials with MDMA being conducted in the future?

Citation formats